[1]李 芹.小儿宝泰康颗粒辅助治疗小儿急性上呼吸道感染的临床疗效及安全性[J].医学信息,2024,37(17):135-138.[doi:10.3969/j.issn.1006-1959.2024.17.029]
　LI Qin.Clinical Efficacy and Safety of Xiao’er Baotaikang Granules in Adjuvant Treatmentof Acute Upper Respiratory Tract Infection in Children[J].Journal of Medical Information,2024,37(17):135-138.[doi:10.3969/j.issn.1006-1959.2024.17.029]
点击复制

小儿宝泰康颗粒辅助治疗小儿急性上呼吸道感染的临床疗效及安全性()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年17期
页码:
135-138
栏目:
中医中药
出版日期:
2024-09-01

文章信息/Info

Title:
Clinical Efficacy and Safety of Xiao’er Baotaikang Granules in Adjuvant Treatmentof Acute Upper Respiratory Tract Infection in Children
文章编号:
1006-1959（2024）17-0135-04
作者:
李 芹
赣州市赣县区妇幼保健院药剂科，江西 赣州 341100
Author(s):
LI Qin
Department of Pharmacy,Ganzhou Gan County District Maternal and Child Health Centre,Ganzhou 341100,Jiangxi,China
关键词:
小儿宝泰康颗粒; 急性上呼吸道感染; 炎症因子; 安全性
Keywords:
Xiao’er Baotaikang granules; Acute upper respiratory tract infection; Inflammatory factors; Safety
分类号:
R272
DOI:
10.3969/j.issn.1006-1959.2024.17.029
文献标志码:
A
摘要:
目的 研究小儿宝泰康颗粒辅助治疗小儿急性上呼吸道感染的临床疗效及安全性。方法 选取2021年5月-2023年4月在我院诊治的68例小儿急性上呼吸道感染患儿为研究对象，采用随机数字表法分为对照组和观察组，各组34例。对照组采用常规西药治疗，观察组在对照组基础上给予小儿宝泰康颗粒辅助治疗。比较两组临床疗效、临床症状（发热、咳嗽、鼻塞、流涕、咽喉肿痛）消失时间、炎症因子水平[C-反应蛋白（CRP）、白细胞介素-18（IL-18）、白细胞介素-6（IL-6）]及不良反应发生率。结果 观察组治疗总有效率（94.12%）高于对照组（82.35%）（P＜0.05）；观察组发热、咳嗽、鼻塞、流涕、咽喉肿痛消失时间均短于对照组（P＜0.05）；两组CRP、IL-18、IL-6均低于治疗前，且观察组均低于对照组（P＜0.05）；观察组不良反应发生率与对照组比较，差异无统计学意义（P＞0.05）。结论 小儿宝泰康颗粒辅助治疗小儿急性上呼吸道感染临床疗效确切，可提高治疗效果，降低炎症因子水平，缩短临床症状消失时间，且不增加不良反应，具有良好的安全性、可行性，值得临床应用。
Abstract:
Objective To study the clinical efficacy and safety of Xiao’er Baotaikang granules in adjuvant treatment of acute upper respiratory tract infection in children.Methods A total of 68 children with acute upper respiratory tract infection diagnosed and treated in our hospital from May 2021 to April 2023 were selected as the research objects. They were divided into control group and observation group by random number table method, with 34 children in each group. The control group was treated with conventional western medicine, and the observation group was treated with Xiao’er Baotaikang granules on the basis of the control group. The clinical efficacy, disappearance time of clinical symptoms(fever, cough, nasal congestion, runny nose, sore throat), levels of inflammatory factors [C-reactive protein (CRP), interleukin-18 (IL-18), interleukin-6 (IL-6)] and incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group (94.12%) was higher than that of the control group (82.35%) (P<0.05). The disappearance time of fever, cough, nasal congestion, runny nose and sore throat in the observation group was shorter than that in the control group (P<0.05). The levels of CRP, IL-18 and IL-6 in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05).Conclusion Xiao’er Baotaikang granules has a definite clinical effect in the adjuvant treatment of acute upper respiratory tract infection in children, which can improve the therapeutic effect, reduce the level of inflammatory factors, shorten the disappearance time of clinical symptoms, and does not increase adverse reactions. It has good safety and feasibility and is worthy of clinical application.

参考文献/References:

[1]石存忠,甄会,刘新桥.复方芩兰口服液治疗急性上呼吸道感染外感风热证的多中心临床评价[J].中国新药杂志,2018,27(9):1012-1018.[2]陈棉.小儿宝泰康颗粒辅助治疗小儿急性上呼吸道感染64例临床观察[J].中医儿科杂志,2017,13(5):50-53.[3]常太芳,程栋.小儿宝泰康颗粒联合头孢呋辛酯治疗小儿上呼吸道感染的临床研究[J].现代药物与临床,2019,34(3):746- 749.[4]Akinyemi JO,Morakinyo OM.Household environment and symptoms of childhood acute respiratory tract infections in Nigeria,2003-2013:a decade of progress and stagnation[J].Bmc Infectious Diseases,2018,18(1):296-303.[5]闫学平,郝秀丽,孙婷,等.血常规联合 hs-CRP、免疫学指标检测在小儿急性上呼吸道感染中的临床价值[J].现代生物医学进展,2018,18(8):1502-1505.[6]王亚军,吴力群,徐勇胜,等.小儿豉翘清热颗粒治疗小儿急性上呼吸道感染的疗效及安全性研究[J].中华医院感染学杂志,2018,28(14):2181-2184.[7]冯霞,程益良.急性上呼吸道感染的中西医联合用药疗效评价[J].中国校医,2019,33(6):472-473.[8]徐旭,黄梦,陈忠波.小儿病毒性上呼吸道感染采用小儿豉翘清热颗粒治疗疗效观察[J].中华中医药学刊,2017,35(5):1330-1332.[9]桑叶,马雅静.WBC、CRP、PCT 检测在儿童急性上呼吸道感染中的诊断价值[J].石河子大学学报,2018,36(1):31-34.[10]赵玉龙,郑艳.对乙酰氨基酚不同给药方式治疗小儿急性发热疗效比较[J].临床合理用药杂志,2018,11(34):100-101.[11]袁彩君,张祎,付品佳.驻马店市某医院儿科门诊上呼吸道感染儿童抗生素使用情况分析[J].华南预防医学,2020,46(1):76-77,81.[12]杨嘉,蔡振荡.小儿豉翘清热颗粒治疗小儿急性上呼吸道感染临床研究[J].新中医,2019,51(5):232-234.[13]张军.小儿柴桂退热颗粒辅助治疗小儿急性上呼吸道感染的效果观察[J].中国妇幼保健,2017,32(14):3236-3238.[14]戎萍,马融,刘全慧,等.中成药治疗小儿急性上呼吸道感染研究述评[J].中国中药杂志,2017,42(8):1455-1466.[15]常太芳.小儿宝泰康颗粒联合头孢呋辛酯治疗小儿上呼吸道感染的临床研究[J].现代药物与临床,2019,34(3):746-749.[16]刘冠彬,付平.小儿宝泰康颗粒联合头孢呋辛对急性上呼吸道感染患儿免疫球蛋白及Th1/Th2免疫应答指标的影响[J].辽宁中医杂志,2022,16(8):112-114.[17]刘军,杨光,沈梦欣,等.小儿宝泰康颗粒对呼吸道病毒感染的抗病毒作用研究[J].药学研究,2022,15(8):190-193.[18]程可平.小儿宝泰康颗粒治疗小儿急性上呼吸道感染的疗效评价[J].基层医学论坛,2021,10(4):67-69.[19]解秀文,郭春艳.小儿宝泰康颗粒治疗小儿急性上呼吸道感染的临床研究[J].世界中医药,2020,8(4):174-176.[20]周丛笑,王俊宏,陈竹,等.小儿风热清合剂治疗小儿急性上呼吸道感染(风热感冒证)的多中心临床研究[J].药物评价研究,2020,20(11):303-305.

相似文献/References:

[1]张 翠.小儿豉翘清热颗粒治疗小儿急性上呼吸道感染的疗效及安全性研究[J].医学信息,2022,35(18):74.[doi:10.3969/j.issn.1006-1959.2022.18.018]
　ZHANG Cui.Study on Efficacy and Safety of Xiaoer Chiqiao Qingre Granules in Treatment of Acute Upper Respiratory Tract Infection in Children[J].Journal of Medical Information,2022,35(17):74.[doi:10.3969/j.issn.1006-1959.2022.18.018]
[2]周 伟,刘学谦,任 翔,等.柴芩清宁胶囊治疗急性上呼吸道感染的系统评价[J].医学信息,2024,37(17):47.[doi:10.3969/j.issn.1006-1959.2024.17.008]
　ZHOU Wei,LIU Xue-qian,REN Xiang,et al.Systematic Evaluation of Chaiqin Qingning Capsule in the Treatment of Acute Upper Respiratory Tract Infection[J].Journal of Medical Information,2024,37(17):47.[doi:10.3969/j.issn.1006-1959.2024.17.008]

更新日期/Last Update: 1900-01-01